Karyopharm Therapeutics Inc. (KPTI)
Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014Q4-CY2013
Balance Sheet Date2025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312023-Sep-302023-Jun-302023-Mar-312022-Dec-312022-Sep-302022-Jun-302022-Mar-312021-Dec-312021-Sep-302021-Jun-302021-Mar-312020-Sep-302020-Jun-302019-Mar-312018-Dec-312018-Sep-302018-Jun-302018-Mar-312017-Dec-312017-Sep-302017-Jun-302017-Mar-312016-Dec-312016-Sep-302016-Jun-302016-Mar-312015-Dec-312015-Sep-302015-Jun-302015-Mar-312014-Dec-312014-Sep-302014-Jun-302014-Mar-312013-Dec-31
Fiscal PeriodQ3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q3-FY2023Q2-FY2023Q1-FY2023Q4-FY2022Q3-FY2022Q2-FY2022Q1-FY2022Q4-FY2021Q3-FY2021Q2-FY2021Q1-FY2021Q3-FY2020Q2-FY2020Q1-FY2019Q4-FY2018Q3-FY2018Q2-FY2018Q1-FY2018Q4-FY2017Q3-FY2017Q2-FY2017Q1-FY2017Q4-FY2016Q3-FY2016Q2-FY2016Q1-FY2016Q4-FY2015Q3-FY2015Q2-FY2015Q1-FY2015Q4-FY2014Q3-FY2014Q2-FY2014Q1-FY2014Q4-FY2013
Operating Cash Flow(5,860,000$)(18,697,000$)(38,984,000$)(25,810,000$)(19,453,000$)(38,498,000$)(43,725,000$)(18,585,000$)(29,530,000$)(25,698,000$)(18,910,000$)(26,843,000$)(28,370,000$)(35,144,000$)(59,197,000$)25,475,000$(23,955,000$)(55,748,000$)(52,888,000$)(30,634,000$)(44,312,000$)(45,011,000$)(39,489,000$)(36,506,000$)(48,204,000$)(66,623,000$)(48,172,000$)(38,665,000$)(34,652,000$)(5,538,000$)(21,750,000$)
Investing Cash Flow4,805,000$18,285,000$15,288,000$14,797,000$7,474,000$51,262,000$21,940,000$26,843,000$(7,685,000$)21,170,000$(32,388,000$)(65,298,000$)11,673,000$(36,596,000$)(14,035,000$)30,770,000$21,426,000$46,458,000$43,186,000$31,397,000$21,431,000$(46,479,000$)(33,519,000$)40,175,000$39,803,000$31,991,000$(103,110,000$)20,566,000$2,484,000$(2,901,000$)20,594,000$
Purchases of Property and Equipment(53,000$)0$0$195,000$0$39,000$0$79,000$207,000$119,000$0$10,000$50,000$107,000$0$49,000$1,093,000$491,000$397,000$382,000$55,000$25,000$0$6,000$39,000$505,000$137,000$596,000$178,000$99,000$2,286,000$324,000$125,000$32,000$
Financing Cash Flow0$680,000$0$264,000$0$155,843,000$5,799,000$1,313,000$30,783,000$896,000$16,000$62,060,000$10,676,000$3,968,000$1,240,000$164,829,000$34,936,000$88,822,000$395,000$152,000$167,776,000$772,000$429,000$22,957,000$160,000$
End Cash Position37,672,000$38,725,000$38,783,000$62,476,000$72,828,000$84,774,000$30,628,000$52,231,000$43,655,000$80,894,000$84,062,000$135,188,000$71,351,000$82,248,000$153,256,000$190,459,000$137,400,000$141,309,000$88,471,000$85,918,000$82,301,000$103,102,000$202,247,000$128,858,000$168,004,000$75,545,000$83,506,000$118,021,000$101,600,000$118,966,000$37,499,000$68,997,000$54,450,000$55,381,000$25,577,000$49,663,000$43,908,000$37,717,000$42,188,000$58,358,000$43,499,000$24,231,000$51,453,000$150,609,000$227,131,000$132,307,000$144,893,000$155,974,000$
Exchange Rate Effect2,000$8,000$5,000$(20,000$)36,000$(11,000$)(16,000$)89,000$(52,000$)(26,000$)(45,000$)126,000$(70,000$)(454,000$)(90,000$)(135,000$)242,000$(64,000$)(91,000$)283,000$17,000$(80,000$)45,000$(35,000$)46,000$(37,000$)(69,000$)35,000$(87,000$)43,000$30,000$70,000$95,000$16,000$
Dividends Paid
Unlevered Free Cash Flow(5,860,000$)(18,697,000$)(38,984,000$)(25,757,000$)(19,453,000$)(38,498,000$)(43,920,000$)(18,585,000$)(29,530,000$)(25,698,000$)(18,910,000$)(26,843,000$)(28,409,000$)(35,144,000$)(59,276,000$)25,268,000$(23,955,000$)(55,748,000$)(52,888,000$)(30,753,000$)(44,312,000$)(45,021,000$)(39,539,000$)(36,613,000$)(48,204,000$)(66,672,000$)(49,265,000$)(39,156,000$)(35,034,000$)(5,593,000$)(21,750,000$)